4-butyrolactone has been researched along with Pulmonary Hypertension in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hanif, K; Jagavelu, K; Shafiq, M; Singh, N | 1 |
| Hanif, K; Jagavelu, K; Kaur, G; Manhas, A; Singh, N | 1 |
2 other study(ies) available for 4-butyrolactone and Pulmonary Hypertension
| Article | Year |
|---|---|
Involvement of fatty acid synthase in right ventricle dysfunction in pulmonary hypertension.
Topics: 4-Butyrolactone; Animals; Animals, Newborn; Cells, Cultured; Fatty Acid Synthase, Type I; Gene Expression Regulation, Enzymologic; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; RNA, Small Interfering; Ventricular Remodeling | 2019 |
Inhibition of fatty acid synthase is protective in pulmonary hypertension.
Topics: 4-Butyrolactone; Animals; Apoptosis; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fatty Acid Synthases; Humans; Hypertension, Pulmonary; Male; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2016 |